Identification and Validation of Three PDAC Subtypes and Individualized GSVA Immune Pathway-Related Prognostic Risk Score Formula in Pancreatic Ductal Adenocarcinoma Patients

Table 1

The relevance among subtypes and clinical data in TCGA-PDAC.

	Subtype 1 (n = 78)	Subtype 2 (n = 17)	Subtype 3 (n = 81)	value
Gender				0.848
Male	40	11	45
Female	38	6	36
Age (average age)				0.763
>65	40 (73.5)	6	37 (74.5)
≦65	38 (60.0)	11	44 (56.5)
Status (dead, %)	34 (43.6)	3 (17.6)	20 (24.7)	<0.01
Residual tumor (R0, %)	41 (52.6)	13 (76.5)	52 (64.2)	<0.01
Tumor size (≤4 cm) (%)	45 (57.7)	11 (64.7)	58 (61.7)	0.236
TNM classification (%)
T1	3 (3.8)	1 (5.9)	3 (3.7)	<0.01
T2	9 (11.5)	6 (35.3)	9 (11.1)
T3&4	66 (84.6)	8 (47.1)	69 (85.1)
Tx (missing)	0	2 (11.8)	0
M0	35 (44.9)	5 (29.4)	40 (49.4)	0.893
M1	2 (2.6)	0	2 (2.5)
Mx (missing)	41 (52.6)	0	39 (48.1)
N0	24 (30.8)	7 (41.2)	18 (22.2)	0.02
N1	54 (69.2)	7 (41.2)	61 (75.3)
Nx (missing)	0	3 (17.6)	2 (2.5)
WHO classification
Stage I	10 (12.8)	6 (35.3)	5 (6.2)	0.02
Stage II	64 (82.1)	9 (52.9)	72 (88.9)
Stage III and IV	4 (5.1)	0	4 (4.9)
Stage x (missing)	0	2 (11.8)	0
Pathological grade
G1	7 (9.0)	11 (64.7)	12 (14.8)	0.02
G2	44 (56.4)	2 (11.8)	48 (59.3)
G3 and G4	27 (34.6)	3 (17.6)	21 (25.9)
Gx (missing)	0	1 (5.9)	0
Alcohol history (YES, %)	49 (62.8)	6 (35.3)	40 (49.4)	0.04
Smoking history (YES, %)	24 (30.8)	5 (29.4)	30 (37.0)	0.248